IN
Ind-Swift Laboratories Ltd (INDSWFTLAB)
₹317.05
Mkt cap
₹3,142 Cr
P/E ratio
34.20
P/B
1.87
Div yield
0.00%
ROE
4.02%
ROCE
4.86%
EPS (TTM)
₹9.27
Book value
₹170
52W range
87–427
Sector
Healthcare
Price history
Previous close
Incorporated in 1995, Ind-Swift Laboratories Ltd is a pharmaceutical company focused on finished dosage formulations (FDF). Co. manufactures tablets, capsules, ointments, injectables, liquids and dry syrups across therapies including gynaecology, paediatrics, cardiology, diabetology and dermatology. Operations span domestic formulations and international markets through own brands, contract manufacturing and out-licensing. [1]
NSE INDSWFTLABBSE 532305
Health check
Cautious
ValuationFair
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−25.68% from high₹317
₹87+263.80% from low₹427
Current
₹317.05
Prev close
₹330.20
Day
−3.98%
Price performance
1D
−4.38%
1W
−12.61%
1M
−8.57%
3M
−5.33%
6M
+133.28%
1Y
+204.34%
YTD
+246.31%
Financials
Revenue, profit & margin
P/E ratio
34.2×
INDSWFTLAB is 1% above the sector median of 34.0×
INDSWFTLAB34.2×
Sector median34.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 290 | 288 | 529 | 33 | 12 | 129 | 138 | 153 | 159 | 151 | 170 | 191 | 240 | |
| YoY Sales growth | -7% | -8% | +74% | -89% | -96% | -55% | -74% | +360% | +1,226% | +17% | +23% | +25% | +52% | |
| Expenses | 224 | 236 | 437 | 43 | 24 | 135 | 147 | 149 | 151 | 147 | 149 | 158 | 195 | |
| Operating Profit | 66 | 52 | 91 | -10 | -12 | -7 | -9 | 4 | 7 | 4 | 21 | 33 | 45 | |
| OPM % | 23% | 18% | 17% | -29% | -99% | -5% | -7% | 2.4% | 4.7% | 2.8% | 12% | 17% | 19% | |
| Other Income | 7 | 7 | 458 | 11 | 13 | 16 | 220 | 15 | 12 | 22 | -3 | 7 | 7 | |
| Interest | 21 | 21 | 3 | 0 | 0 | 10 | -27 | 1 | 2 | 1 | -2 | 1 | 1 | |
| Depreciation | 13 | 14 | 20 | 0 | 0 | 6 | 7 | 7 | 7 | 9 | 8 | 8 | 8 | |
| Profit before tax | 39 | 24 | 527 | 1 | 1 | -7 | 230 | 10 | 10 | 16 | 12 | 33 | 43 | |
| Tax % | 18% | 19% | 6% | -3% | 31% | -16% | 4% | 17% | 22% | 42% | -26% | 25% | 21% | |
| Net Profit | 32 | 19 | 494 | 1 | 0 | -5 | 222 | 9 | 8 | 10 | 15 | 25 | 34 | |
| EPS in Rs | 5.36 | 3.29 | 83.55 | 0.16 | 0.07 | -0.93 | 36.67 | 1.45 | 0.98 | 1.17 | 1.74 | 2.84 | 3.94 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202642.93%Promoter
Promoters42.93%
FIIs10.78%0.08
DIIs0.20%0.03
Public46.09%0.10
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,880.00 | 36.66 | 4,51,075 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,442.00 | 88.89 | 3,03,749 | 0.26% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,670.00 | 81.82 | 1,77,632 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,424.00 | 97.75 | 1,30,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,189.90 | 26.20 | 1,18,693 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,380.00 | 41.17 | 1,15,267 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,391.80 | 36.21 | 1,12,442 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Ind-Swift Labs. | ₹361.30 | 34.24 | 3,142 | 0.00% | 34 | +334.04% | 240 | +51.58% | 4.86% |
| Median: 160 Co. | ₹465.83 | 33.99 | 2,012 | 0.08% | 13 | +33.53% | 179 | +20.92% | 14.94% |
Filings
Annual reports15
Concall transcripts10
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Earnings Call Transcript 10 Nov - Transcript for earnings call held on November 04, 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 4 Nov - Audio recording of Q2 FY26-27 earnings conference call made available on 4 November 2026.Announcement under Regulation 30 (LODR)-Investor Presentation 4 Nov - Investor presentation on un-audited financial results for the quarter ended September 30, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency Report 3 Nov - CARE issued Q2FY27 monitoring report for Rs137.20 crore preferential warrants, with no deviationobjects.Announcement under Regulation 30 (LODR)-Monitoring Agency Report 3 Nov - CARE final report says Rs 314.60 crore preferential proceeds fully utilized; warrant lapse caused Rs 58.99 crore shortfall.






